230 results about "Type diabetes" patented technology

The invention relates to fusion protein used to prevent and cure I type and II type diabetes and its preparation method and application. It supplies the fusion protein which is formed by glucagon analogy peptide GLP-1, GLP-1 mutant and IgG-Fc, its analogy factor lizard salivary gland polypeptide extendin-4 and IgG-Fc, and the application of the above fusion protein and its DNA used in diabetes prevention and therapy. The fusion protein can increase not only GLP-1 effect, but also the affinity and immunological tolerance of ligand, which is excreted with the form of homogeneity dimmer to improve polypeptide drug effect, overcomes the defect of the GLP-1 for short half-life, and simplifies purification process.

The invention relates to a dual blood sugar and blood fat adjusting fusion protein and a preparation method and application thereof. The invention provides the fusion protein of a human fibroblast growth factor 21 (FGF-21), a glucagon similar peptide 1 (GLP-1) and an analog thereof (Exendin-4), a DNA sequence for coding the fusion protein, a vector containing the DNA sequence, a host cell containing the vector, a method for preparing the fusion protein by using gene engineering, and a medicinal composition of the fusion protein. The fusion protein of the invention has the activities of the FGF-21 and the GLP-1 at the same time, and can be used as a treatment medicament of obesity, II-type diabetes and hyperlipidemia.

The invention relates to a method for judging 2 type diabetes mellitus risk state and belongs to the technical field of biomedicine. The method includes that EM clusters and C4.5 classification are utilized to extract determinant attributes affecting attack of the 2 type diabetes mellitus, the crowd is divided into different cluster groups according to own characteristics, according to determinant attributes extracted results and a Logistic regression method, personal or crowd risk state is judged by combining metabolic syndrome and high risk group criterions. The determinant attributes affecting the 2 type diabetes mellitus are obtained, simultaneously, different risk state judgment models are built based on different characteristics of the crowd, the universality and practicability of the models are improved, the requirements of real-time processing and mobile computation are met, the effective degree of the determinant attributes is estimated through a quantitative analysis method, the complexity is low, the accuracy is high, and the divided risk state is detailed.

The invention belongs to the field of medical technology, and particularly relates to a glucoside derivate shown as a formula (I), and a medically acceptable salt, an ester easily hydrolyzed, a stereoisomer and an itnemrediate of the glucoside derivate, and a preparation method of the compounds and the intermediate, in particular to a glucoside derivate which is served as a sodium-glucose co-transporter (SGLT) inhibitor, a medically acceptable salt, an ester easily hydrolyzed, a stereoisomer and an itnemrediate of the glucoside derivate, and a preparation method of the compounds and the intermediate. The glucoside derivate provided by the invention can be used for treating diabetes mellitus such as insulin dependent diabetes mellitus (I type diabetes mellitus) and non-insulin dependent diabetes mellitus (II type diabetes mellitus), and also can be applied to treating insulin resistance diseases and various diseases relevant to diabetes mellitus of fat, and preventing such diseases, wherein R1, R2, R3, R4, R5, R6, R7, R7a, R7b, R7c, X, n and A are defined as shown in the specification.

The present invention belongs to the technical field of crop cultivation and food processing and production, and provides a quinoa high-yield close-planting cultivation method and a quinoa tea preparation method, which aim to solve the problems that the conventional quinoa planting and cultivation technology severely affects sustainable development of quinoa cultivation, requirements of people on non-harmful products cannot be met, and saponin cannot be removed thoroughly nutrient element loss is severe when quinoa is prepared into quinoa tea. The cultivation method comprises the following steps: selecting land, plowing, applying fertilizer, sowing seeds, thinning, cultivating earth and preventing and controlling diseases and insect pests; the yield per mu (a unit of area) can be increased to 20-80 kg; the cultivation method is applicable to large-scale field extended cultivation; the cost is reduced greatly, and sustainable development of quinoa planting is facilitated; and high yield and no harm of quinoa are ensured. The quinoa tea also has a ginseng fragrance and a mellow taste, and soaked quinoa is edible; and the quinoa tea has significant effects of balancing and supplementing nutrition, strengthening body functions, repairing physical conditions, regulating immunity and internal secretion, improving body stress ability, preventing diseases (cardio-cerebrovascular disease and II type diabetes), resisting cancer, losing weight, assisting in treatment and the like.

The invention discloses a glimepiride dispersible tablet and a preparation method thereof. The dispersible table is prepared by micronizing the medicament glimepiride to control the grain diameter to be lower than 10 mu m, and adding auxiliary materials. According to the prepared dispersible tablet, the stability and absorption rate of the medicament are remarkably improved, and the bioavailability and curative effect are increased, so that the dose is reduced, toxic and side effects caused by the medicament are lightened, and the problems of low dissolution rate and the like of the conventional glimepiride tablets are solved. The method is suitable for the glimepiride dispersible tablet, which is mainly used for treating II-type diabetes mellitus which cannot be controlled in diet control and exercise.

The invention discloses application of a traditional Chinese medicine composition in preparing a medicament of an insulin sensitizer and in preparing a medicament of an angiotensin converting enzyme inhibitor. The traditional Chinese medicine composition consists of 17 kinds of traditional Chinese medicines of ginseng, rhizoma polygonati, rhizoma atractylodis, radix sophorae falvescentis and the like. Through benefiting vital energy and nourishing Yin, invigorating spleen and promoting body fluid, the invention can not only effectively improve and treat insulin resistance of II-type diabetes mellitus for treating II-type diabetes mellitus suitably, but also can effectively restrain activity of angiotensin converting enzyme for treating hypertension with obvious effect.

The invention aims at disclosing a virtual screening method of an alpha-glucosidase inhibitor, the virtual screening method and the application of screened compounds in pharmaceutical preparations forpreventing and/or treating 2-type diabetes. The method comprises the steps of 1, the obtaining, analyzing and treating of the three-dimensional structure of a large molecular protein; 2, the construction of a traditional Chinese medicine natural product library and the preparation of a small molecular compound; 3, the calibration of the prediction capability of a virtual screen model and the establishment of the screen model; 4, the virtual screening of the natural product library and the analyzing of a mutual impacting mechanism; 5, in vivo and in vitro biological activity verification of ascreening result. The method is used for screening and can be used for the discussing of a structure-activity relationship of compounds of the type, and the further modification of a structure based on a biological compound is guided.

The invention relates to a synthesis method of bulk drug of anagliptin for treating II type diabetes, and aims to solve the problem that at present there is no industrial synthesis method of anagliptin. The synthesis method comprises the following steps: (1) taking vinyl ethyl ether and trichloroacetic chloride as the raw materials, carrying out three-step reactions to obtain an intermediate (4) with a protected aldehyde group; carrying out dehydration condensation between the intermediate (4) and 3-amino-5-methylpyrazole to obtain pyrazolopyrimidine parent nucleus; and hydrolyzing carboxyl ethyl ester to obtain 2-methyl-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid6; (2) taking L-proline as the raw material, subjecting L-proline to methyl esterification, ammoniation, acetylation, and cyaniding reactions to obtain a chiral cyanopyrrole intermediate (11); making the chiral cyanopyrrole intermediate (11) and a diamine segment (12) carry out nucleophilic substitution reactions under an alkaline condition to obtain an intermediate (13), and finally removing the Boc protective group from the intermediate (13) in the presence of hydrochloric acid to obtain a cyanopyrrole amine intermediate (14); (3) coupling 2-methyl-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 6 with the cyanopyrrole amine intermediate (14) under condensation conditions so as to obtain the bulk drug anagliptin.

The invention provides application of novel glucagon peptide 1 fatty acid modified or unmodified dimer different in configuration in pancreas protection or hypoglycemic effect during treatment of II-type diabetes. The dimer is formed by connecting two identical GLP-1 monomers containing cysteine through disulfide bond formed by cysteine oxidation. Hypoglycemic duration of GLP-1 dimer is remarkablyprolonged without lowering activity of H-shaped GLP-1 homodimer (the disulfide bond is formed inside peptide chain), in-vivo continuous activity of GLP-1 analogue dimer can last for 19d while in-vivoactivity of liraglutide which is positive control drug is 3d, or in-vivo activity duration is remarkably prolonged when compared with long-acting GLP1 similar peptide which has already been reportedat present, so that technical progress of long-acting GLP1 drug is greatly promoted while convenience is brought to clinical application and popularization of the same. U-shaped homodimer (the disulfide bond is formed at the terminal C of the peptide chain) does not have impact on blood glucose but can obviously protect exocrine portion cells like pancreatic acini and catheters, thereby having a pancreas protecting function.

The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.

The invention discloses a traditional Chinese medicine preparation for treating type-2 diabetes, and the traditional Chinese medicine preparation is prepared by the following raw materials according to the mixture ratio by weight: 10-20 parts of radix salviae albae, 10-15 parts of membranous milkvetch root, 10-15 parts of dried rehmannia root, 6-12 parts of barbary wolfberry fruit, 10-15 parts of Mongolian snakegourd root, 5-10 parts of common anemarrhena rhizome, 5-10 parts of kudzuvine root and 1-2 parts of liquoric root. In addition to a certain hypoglycemic effect, the traditional Chinese medicine preparation can significantly improve the type-2 diabetes, in particular to the symptoms of dry mouth and throat, malaise, fatigue, soreness and weakness of waist and knees, burning heat, insomnia, blurred vision, dizziness, heart palpitations, limb numbness and pain, and the like of patients with deficiency of both qi and yin and the blood stasis type diabetes. The greatest feature of the traditional Chinese medicine preparation to be different from the existing technologies is that the radix salviae albae which is the special local herbal medicine in Shandong is firstly applied in the formula for treating the diabetes, thereby effectively improving the clinical treatment effect.

The present invention relates to a self-body antibody detection method for immune mediated diabetes type A diagnosis, belonging to the field of biological medicine technology. Said invention includes the following steps: (1), using reverse transcriptive enzyme to make mRNA undergo the process of reverse transcription. Then using high fidelity DNA polymerase to respectively synthesize target DNA, using ligase and protein expression plasmid to make connection, making it be transformed into colibacillus to respectively express target protein; (2), using maltose-binding protein affinity chromatographic column and GST affinity chromotographic column to purify and separate out expression protein, dividing every purified expression protein into two portions; (3), coating antigen: making four antigens be mixed in the coating buffer solution, adding coating buffer solution in every enzyme-labeled well, standing still; (4), closing; and (5), using double-antigen sandwich method to determine antibody. Said invention can once detect any one or several kinds of antibodies of GAD65, IA2, Phogrin and ICA 69.

The invention provides a composition for preparation of foods or drugs for preventing, improving or treating type II diabetes. The composition comprises sea cucumber total saponins or a sea cucumber saponin. Results of animal experiments show that the sea cucumber total saponins or the sea cucumber saponin can reduce obviously a fasting blood glucose value and improve significantly an insulin resistance thus has obvious effects of improving, preventing or treating II type diabetes and can be utilized alone and adopted as a component or an auxiliary material to be prepared into foods or drugs.The preparation method of the sea cucumber saponin-containing composition has the advantages of low cost, simple processes and less pollution of organic solvents on environment. Results of an animal experiment show that the sea cucumber saponin-containing composition have good effects of improving, preventing or treating II type diabetes and can be utilized for development of foods or drugs for improving, preventing or treating II type diabetes.

The invention relates to a compound for preventing and treating metabolic diseases such as hyperlipemia, atherosclerosis, II type diabetes, and the like as well as application thereof. The invention discloses an inhibitor of a new SREBP (Sterol Regulatory Element Binding Protein) path. The inhibitor can be used for specifically inhibiting the lipophilic synthesis of cholesterin, fatty acid and triglyceride and reducing the lipid level, thereby providing a new path for preventing and treating the metabolic diseases such as adiposity, atherosclerosis, II type diabetes, and the like.

The invention belongs to the field of traditional Chinese medicine manufacturing, and relates to application of leonurine to preparation of a medicament for treating 2-type diabetes. Animal experiments prove that the fasting blood glucose of a 2-type diabetes mouse, i.e., a db/db mouse, can be lowered by the leonurine, and the tolerance of oral glucose is improved; and meanwhile, fasting plasma insulin is increased, the plasma triglyceride is reduced and the content of the plasma high-density lipoprotein is increased. Experiment results also show that the expression of liver glucose metabolic enzymes such as glucokinase, glucose-6-phosphatase and phosphoenolpyruvate carboxyl enzyme is adjusted by the leonurine in an Akt dependent mode; and the biological response of an inflammatory mediator, such as generation of TNF (Tumor Necrosis Factor)-alpha, degradation of IkB-alpha and subsequent phosphorylation of NF-kBp65, is suppressed. Through the leonurine, the inflammatory state of the 2-type diabetes can be corrected, and the symptoms of the 2-type diabetes can be improved; and the leonurine can be used as a treatment medicament to be applied to the treatment of the 2-type diabetes.

The invention discloses a new application of theabrownin in the pharmaceutical field. The theabrownin of the invention is a natural product which uses black tea or pu'er tea as a raw material and is extracted from the tea. The result of pharmacological experiments indicates that the theabrownin has the function of markedly restraining protein tyrosine phosphatase. The theabrownin can also be used for preventing or curing II type diabetes, fat diabetes and adiposis. As the theabrownin is the natural product extracted from the black tea or pu'er tea, thus enjoying the advantages of no toxicity and side effect, safe and reliable use.

The invention provides a new medical application of a Chinese traditional medicine fructus ligustri lucidi and the producing method of the extract thereof, which is produced by following steps: ethanol circumfluence, extracting and concentrating from the plant fructus ligustri lucidi to get an ethanol extract, separation by crystallization with the hydrochloric acid function, NaOH treating, again acid out, washing, drying, obtaining other effective components. Pharmacological experiments prove that the medicine can be used for treating the II-type diabetes and induced complication, which has the effects such as reducing the blood sugar, triglyceride, total cholesterin, and low density lipoprotein, and increasing the high density lipoprotein and etc. Furthermore, it can avoid the weight decrease and has a long action and no side effects.

The invention provides a compound preparation for treating II type diabetes mellitus and a preparation method of the compound preparation. The pharmaceutical composition for treating II type diabetes mellitus is prepared from active components ipragliflozin and metformin hydrochloride as well as pharmaceutical adjuvants including a filler, an adhesive, a disintegrant and a lubricant. The compound preparation for treating II type diabetes mellitus prepared by the method has no special requirements on particle sizes of the active components, is free of superfine grinding, low in energy consumption, high in dissolution rate and high in bioavailability, and has a market development prospect; and the defects of poor dissolution rate and low bioavailability of the active components are solved.

A GLP-1 analog can be used to decrease blood sugar and treat ó�type diabetes mellitus. It has higher efficiency and better stability. Also, Preparation of the said polypeptide is involved.